Evidence map›Paper›PMID 38545151›Full record

ArticleHeliyon2024

Application of artificial intelligence based on the fuzzy control algorithm in enterprise innovation.

Yanhuai Jia, Zheng Wang

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yanhuai JiaSchool of Business, Macau University of Science and Technology, Macau, 999078, China.
Zheng WangDepartment of Business Administration, Shanghai University of Finance and Economics Zhejiang College, Jinhua, 312000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial Intelligence (AI) has gained immense popularity in recent years as many enterprises have realized their potential to change the way of conducting business innovatively. The new concepts, items, or procedures are developed and implemented within a business or organization to enhance productivity, effectiveness, and competitiveness, and this is called Enterprise Innovation (EI). AI techniques are required to make decisions more effectively in challenging and dynamic situations, like EI, as result of competitive marketplace. Hence, an intelligent, innovative strategy with Q-learning and Takagi Sugeno Fuzzy Control (Q-TSFC) algorithm has been proposed as it combines adaptive learning and Fuzzy Logic (FL) that humans understand to improve decision-making in enterprise innovation. Q-learning seeks to maximize the enterprise's profit by utilizing the newly acquired knowledge, exploring activities, and adaptive learning based on the optimal ε greedy policy that results with rewards and the experiences. To develop a framework for making decisions and connections between input from the learned Q values and output decisions using enterprise expertise and linguistic conventions. The objective is to handle language uncertainty and imprecision in market trend. So, it leads to right decisions even without accurate numerical facts. The proposed approach is validated by evaluating metrics like cost savings, customer satisfaction, and innovation performance efficiency in the competitive edge in the market. With this proposed Q-TSFC algorithm, the obtained results are 96.5% customer satisfaction ratio, 96% enterprise performance efficiency, cost savings of about 48% profitable value, and the coefficient of determination R

Indexed as

Artificial intelligenceEnterprise innovationFuzzy controlProduct innovationQ-learningTakagi sugeno

Identifiers

PMID38545151
PMCPMC10965512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.